wsbdaily | Mon, 26 Sep 2022 03:58:39 EST Where you find Tomorrow’s Hot Stocks Yesterday!
NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
Evofem Biosciences, Inc.(EVFM)
Evofem Biosciences, Inc.
12400 High Bluff Drive
Suite 600
San Diego, CA 92130
United States
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Summary & Charts
| Price | $ 0.19 | -0.01 (-4.91%) |
| Day's Range | $ 0.19 - 0.23 | |
| Previous Close | $ 0.20 | |
| Market Cap | $ 16.92M USD | |
| Short Interest % | N/A | |
| Float | N/A | |
| Outstanding | N/A |
| Exchange | Other OTC | |
| Industry | Biotechnology | |
| Sector | Healthcare | |
| Volume | 3.40M | |
| Avg. Volume (20 day) | 1.76M | |
| Rel. Volume (20 day) | 1.93 | |
| Rel. Volume (3 month) | 0.10 | |
| Rating | B+ | Neutral |
| DCF | N/A | Strong Buy |
| Debt/Equity | -124.76 % | Sell |
| ROE | 225.66 % | Strong Buy |
| ROA | -530.13 % | Strong Sell |
| P/E | -0.02 % | Neutral |
| P/B | -0.02 % | Neutral |
| Date | Open | High | Low | Close | Change | Volume | R. Vol. (20d) | R. Vol. (3m) | Mentions |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2022 | $ 0.22 | $ 0.23 | $ 0.19 | $ 0.19 | -0.01 | 3,398,946 | 1.93 | 0.10 | |
| Sep 22, 2022 | $ 0.19 | $ 0.22 | $ 0.17 | $ 0.20 | +0.02 | 3,285,792 | 1.95 | 0.10 | 2 |
| Sep 21, 2022 | $ 0.20 | $ 0.20 | $ 0.16 | $ 0.18 | -0.02 | 3,382,227 | 2.09 | 0.11 | 2 |
| Sep 20, 2022 | $ 0.22 | $ 0.23 | $ 0.19 | $ 0.20 | -0.02 | 2,632,201 | 1.77 | 0.08 | 1 |
| Sep 19, 2022 | $ 0.25 | $ 0.28 | $ 0.21 | $ 0.22 | -0.04 | 3,729,895 | 2.65 | 0.12 | |
| Sep 16, 2022 | $ 0.29 | $ 0.30 | $ 0.25 | $ 0.26 | -0.04 | 5,801,530 | 4.50 | 0.19 | |
| Sep 15, 2022 | $ 0.30 | $ 0.31 | $ 0.29 | $ 0.30 | -0.00 | 763,237 | 0.68 | 0.02 | 1 |
| Sep 14, 2022 | $ 0.32 | $ 0.34 | $ 0.28 | $ 0.31 | -0.03 | 1,955,396 | 1.66 | 0.06 | |
| Sep 13, 2022 | $ 0.34 | $ 0.34 | $ 0.32 | $ 0.33 | +0.00 | 431,753 | 0.34 | 0.01 | |
| Sep 12, 2022 | $ 0.33 | $ 0.36 | $ 0.32 | $ 0.33 | -0.01 | 467,433 | 0.33 | 0.02 | |
| Sep 09, 2022 | $ 0.33 | $ 0.35 | $ 0.33 | $ 0.34 | +0.01 | 672,552 | 0.40 | 0.02 | |
| Sep 08, 2022 | $ 0.31 | $ 0.34 | $ 0.30 | $ 0.33 | +0.03 | 634,279 | 0.32 | 0.02 | |
| Sep 07, 2022 | $ 0.31 | $ 0.32 | $ 0.29 | $ 0.30 | -0.01 | 633,541 | 0.14 | 0.02 | 1 |
| Sep 06, 2022 | $ 0.32 | $ 0.32 | $ 0.30 | $ 0.31 | -0.01 | 760,368 | 0.13 | 0.03 | 1 |
| Sep 02, 2022 | $ 0.32 | $ 0.34 | $ 0.30 | $ 0.32 | +0.00 | 745,653 | 0.11 | 0.02 | 1 |
| Sep 01, 2022 | $ 0.35 | $ 0.35 | $ 0.30 | $ 0.32 | -0.03 | 1,355,318 | 0.16 | 0.04 | |
| Aug 31, 2022 | $ 0.37 | $ 0.39 | $ 0.33 | $ 0.35 | -0.02 | 1,202,768 | 0.13 | 0.04 | |
| Aug 30, 2022 | $ 0.38 | $ 0.40 | $ 0.36 | $ 0.37 | -0.01 | 787,088 | 0.08 | 0.02 | |
| Aug 29, 2022 | $ 0.38 | $ 0.40 | $ 0.37 | $ 0.38 | +0.00 | 666,661 | 0.06 | 0.02 | |
| Aug 26, 2022 | $ 0.40 | $ 0.42 | $ 0.36 | $ 0.37 | -0.03 | 1,854,701 | 0.17 | 0.06 |
News
The latest news about Evofem Biosciences, Inc. (EVFM).
Seeking Alpha | 2022-08-04 23:27:10
Evofem Biosciences, Inc. (NASDAQ:EVFM ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Amy Raskopf - Vice President-Investor Relations Saundra Pelletier - Chief Executive Officer, President and Executive Director Jay File - Chief Financial Officer Katherine Atkinson - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Yale Jen - Laidlaw and Company Stacy Lee - Stifel Ram Selvaraju - H.C. Wainwright Operator Good afternoon.
PRNewsWire | 2022-07-28 08:47:00
-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO , July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows: Date: Thursday, August 4, 2022 Time: 5:00 pm.
Earnings
| Date | Time | EPS Expected | EPS Reported | % | Revenue Expected | Revenue Reported | % |
|---|---|---|---|---|---|---|---|
| 2022-08-12 | AMC | -0.98 | -4.57 | 366.32% | -- | -- | -- |
| 2022-05-10 | AMC | -3 | -- | -- | 4.3M | 4.3M | -- |
| 2022-03-03 | AMC | -0.23 | -0.33 | 43.47% | 4.2M | 3.6M | -13.98% |
| 2021-11-15 | AMC | -0.29 | -0.48 | 65.51% | 1.5M | 1.7M | 17.17% |
| 2021-08-11 | AMC | -0.35 | -0.27 | 22.86% | 2.7M | 1.9M | -30.71% |
| 2021-05-06 | AMC | -0.49 | -0.56 | 14.28% | 1.6M | 1.1M | -32.21% |
| 2021-03-04 | AMC | -0.36 | -0.50 | 38.88% | 1.7M | 168K | -90.06% |
| 2020-11-09 | AMC | -0.44 | -0.37 | 15.91% | 322K | 278K | -13.73% |
Top Discussions
These are the top discussions over the last 24-hours that mention the EVFM stock ticker symbol.
Failures to Deliver
Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.
Last Updated: Tue, 14 Dec 2021 12:00 EST
@wsbdaily
wsbdaily